Clinical-stage biotechnology company developing cerebroprotective therapies that target astrocytes to reduce brain damage and support recovery after traumatic brain injury, concussion, stroke, and neurodegenerative disease
Clinical-stage biotechnology company developing cerebroprotective therapies that target astrocytes to reduce brain damage and support recovery after traumatic brain injury, concussion, stroke, and neurodegenerative disease. Its lead candidate AST-004 is advancing through Phase 2 development.